Navigation Links
CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
Date:1/7/2009

Results expected to Support Licensing Activities

VIENNA, Va., Jan. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Alternext US: CVM) announced today the initiation of a definitive study of its new rheumatoid arthritis treatment vaccine (CEL-2000) to determine the long-lasting beneficial effects on animals with the disease. The study is being conducted at the request of a large pharmaceutical company which is evaluating the possibility of acquiring a global license for the vaccine from CEL-SCI. The long-term results, previously presented at the 6th annual GTCbio Vaccine conference, for the CEL-2000 vaccine were better than or comparable to those for Enbrel(R), a leading treatment for people with rheumatoid arthritis.

"We are very excited to see a prominent pharmaceutical company express interest in licensing the vaccine," said Geert Kersten, CEL-SCI's Chief Executive Officer. "As a result of the very good data with this novel approach, we believe that the prospects for licensing the vaccine are promising."

The definitive experiment will confirm the efficacy and durability of the response to the vaccine and will further assess the safety of the CEL-2000 vaccine, in preparation for possible human trials. CEL-2000 may also offer a number of other potential advantages over existing rheumatoid arthritis treatments, such as Enbrel. The data from animal studies of rheumatoid arthritis using CEL-2000 treatment vaccine demonstrated that CEL-2000 is an effective treatment against arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments, including Enbrel(R). CEL-2000 is also potentially a more disease type specific therapy is calculated to be significantly less expensive and may be useful in patients unable to tolerate or who may not be responsive to existing anti-arthritis therapies.

Rheumatoid arthritis treatments comp
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
2. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
3. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
6. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
7. Surf Sweets Launches Natural, Organic Candy Line at More Than 250 Toys"R"Us Stores Across the Country
8. ChildRC.com Launches The Child Resource Center
9. First Service Design Firm Launches in United States
10. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
11. Florida Breast Augmentation Surgeon Launches State-of-the-Art Website Reflecting his Unique Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial Plastic ... non-surgical double-chin eliminator. Dr. Stong is double board ... to offer Kybella treatments . The FDA recently ... the chin, promising to safely dissolve fat deposits and ... sought immediate solutions for their double chin were forced ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... (ACE) has just released the first-ever congenital ... Congenital Cardiac Catheterization Laboratory (PCCL) accreditation. Driven ... CHD standards are a comprehensive review of ... with congenital heart disease. , “The ACE ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... tests separately predict the likelihood that a patient,s breast ... the cancer,s vulnerability to chemotherapy or hormone therapy, researchers ... Center report at the first American Society of Clinical ... Francisco. , Each predictor - of prognosis, of ...
... to headline Boston forums, BOSTON, Sept. 7 ... and former Republican,Governor Mike Huckabee (AR) will address ... 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ) ... AARP,s annual,member event. The candidates will address AARP,s ...
... PA, Sept. 7 /PRNewswire-FirstCall/ - MDS Pharma,Services, a ... has won the Good Clinical Practice Journal (GCPj) ... access to new medicines. This,award is one of ... year to,recognize excellence in clinical research. MDS Pharma ...
... hours of instruction improved relationships with patients, study claims ... evidence suggests that a bit of theatrics can help ... on the experience of a small group of internal ... workshops and lectures led by university theater professors. , ...
... October 16, 2007, SUNNYVALE, Calif., Sept. 7 ... has set October 16, 2007, as the,date of the ... with a wholly owned subsidiary of Medtronic. The ... Time, at,Kyphon,s corporate headquarters located at 1221 Crossman Avenue, ...
... LifeQuest World,Corporation (formerly PhytoLabs Inc.) announced today that the ... contest to allow the,public to participate in choosing a ... 30, 2007. The company was unable to use any ... prize of a trip for two to,Las Vegas was ...
Cached Medicine News:Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 2Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 3Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 4Health News:Presidential Candidates Address Health, Financial Security at AARP's Life@50+ 2Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 2Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 3Health News:LifeQuest Announces End of Immunity Health Challenge Contest 2
(Date:5/4/2015)... N.J. , May 4, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... multiple countries worldwide, will report Q1 2015 financial ... 11, 2015.  CytoSorbents, management will ... that will recount both operational and financial progress ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - YOLO ... the manufacturing and distribution of medical and aesthetic ... market clearance for YOLO,s new generation body contouring ... has completed its second-generation low-level laser device for ... advancements to our patented technology while continuing to ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... notification from the Food and Drug Administration ("FDA" or the ... March 31, 2015, has been placed on clinical hold pending ... related to the stability of the drug substance and drug ... The Company had sought approval of their IND application ...
Breaking Medicine Technology:CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3YOLO Medical Inc. receives FDA clearance for body contouring laser 2ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4
... HONG KONG, Sept. 20, 2011 /PRNewswire-Asia/ -- Golden ... subsidiaries collectively as the "Group," - 801.HK; 910801.TW), a ... of 2.0% interest in FunTalk China Holdings Limited, the ... the Group,s effective interest in FunTalk China will be ...
... NEW YORK, September 20, 2011 Preetha ... the United Nations Summit at New York held by ... of Non-Communicable Diseases. Non-communicable diseases, such as ... disease, account for more than 63 percent of all ...
Cached Medicine Technology:Golden Meditech Disposes of 2.0% Stake in FunTalk China for US$15 Million 2Preetha Reddy, Managing Director, Apollo Hospitals Invited to United Nations Summit on NCDs 2
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: